CRS Clinical Research Services Kiel GmbH
Kiel, Schleswig-Holstein, 24105, Germany
NCT Number: NCT06589713
The purpose of this study is to assess the effect of renal impairment on the pharmacokinetics of enpatoran.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 1
Kiel, Schleswig-Holstein, 24105, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For Control Group 1 (Normal Renal Function):
For Group 2 (Impaired Renal Function):
Exclusion criteria
Participants will receive a single oral dose of enpataron tablets once daily.
Time frame: Predose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 hours postdose
Time frame: Up to Day 35
Time frame: Baseline and up to Day 35
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Industry
Phase 1, Open Label, Single Dose Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Enpatoran in Male and Female Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03896750
Actinomycetales Infections, Bacterial Infections
Miami, Florida, United States
View Trial DetailsNCT03289208
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Tokyo, Japan
View Trial DetailsNCT07217886
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Orlando, Florida, United States
View Trial DetailsNCT06671444
Dyssomnias, Female Urogenital Diseases
Nanjing, Jiangsu, China
View Trial Details